Table 2 |
|
Challenges in conducting therapeutic trials in Wegener's granulomatosis |
| Rarity of Wegener's granulomatosis |
| Potential for active disease to be life threatening |
| Available treatment of established efficacy |
| Definition of outcome measures |
| Imprecise means of assessing active disease |
| Extended follow-up is necessary to fully assess relapse and to reach study endpoints |
|
|
|
Langford Arthritis Res Ther 2003 5:180 doi:10.1186/ar771 |